Adicet Bio is a clinical-stage biopharmaceutical company developing medicines that target the biology of aging to prevent or treat age-related diseases with the potential to extend healthy lifespan. Co.'s main program selectively inhibits the target of rapamycin complex 1 (TORC1), a conserved pathway that contributes to the age-related decline in function of multiple organ systems. Co.'s product candidate, RTB101, is an oral and selective inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Co. has licensed the rights to its TORC1 program, including RTB101 alone or in combination with everolimus, from Novartis International Pharmaceutical Ltd. We show 46 historical shares outstanding datapoints in our coverage of ACET's shares outstanding history.
Understanding the changing numbers of ACET shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACET versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACET by allowing them to research ACET shares outstanding history
as well as any other stock in our coverage universe. |
Free ACET Email Alerts:
Video: Shares Outstanding Importance
